Reduction of clozapine-induced hypersalivation by pirenzepine is safe

Pharmacopsychiatry

Volumn 37, Issue 2, 2004, Pages 43-45

  Schneider, B ^a   Weigmann, H ^b   Hiemke, C ^b   Weber, B ^a   Fritze, J ^a,c  

^a GOETHE UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Ger Assoc of Priv Health Insurers

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENPERIDOL; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; BROMOCRIPTINE; BROMPERIDOL; CHLORPROTHIXENE; CLOZAPINE; DIAZEPAM; DOXEPIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM CARBONATE; LORAZEPAM; NEUROLEPTIC AGENT; NORCLOZAPINE; PIRENZEPINE; THIORIDAZINE; TIAPRIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERSALIVATION; MALE; PILOT STUDY; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; STEADY STATE; ULTRAVIOLET RADIATION;

ADULT; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PILOT PROJECTS; PIRENZEPINE; SCHIZOPHRENIA; SIALORRHEA; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 2442630250     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-815523     Document Type: Article

References (15)

1. Bai YM, Lin CC, Chen JY, Liu WC. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Psychopharmacol 2001; 21: 608-611
2. Brieden T, Ujeyl M, Naber D. Psychopharmacological treatment of aggression in schizophrenic patients. Pharmacopsychiatry 2002; 35: 83-89
3. Brown ES, Thomas NR, Carmody T, Mahadi S, Nejtek VA. Atypical antipsychotics in bipolar and schizoaffective disorders. Pharmacopsychiatry 2001; 34: 80-81
4. Copp PJ, Lament R, Tennet TG. Amitriptyline in clozapine-induced sialorrhoea. Br J Psychiat 1991; 159: 1606-1607
5. Davydov L, Botts SR. Clozapine-induced hypersalivation. Ann Pharmacother 2000; 34: 662-665
6. Dettling M, Sachse C, Brockmöller J, Schley J, Müller- Oerlinghausen B, Pickersgill I, et al. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology 2000; 152: 80-86
7. Fritze J, Elliger T. Pirenzepine for clozapine-induced hypersalivation. Lancet 1995; 346 (8981): 1034
8. Hagg S, Spigset O, Mjorndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2000; 49: 59-63
9. 2 (Pirenzepin) an Ratte, Kaninchen und Hund. Therapiewoche 1977; 27: 1567-1574
10. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiat 1988; 45: 789-796
11. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiat Scand Suppl 1987; 334: 1-100
12. Naber D, Lambert M, Krausz M, Haasen C. Atypische Neuroleptika in der Behandlung schizophrener Patienten. Bremen: Unimed Verlag, 2000
13. Olesen OV, Linnet K. Fluvoxamine - Clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. J Clin Psychopharmacol 2000; 20: 35-42
14. Rabinowitz T, Frankenburg FR, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiat 1996; 40: 1132-1134
15. Weigmann H, Bierbrauer J, Härtter S, Hiemke C. Automated determination of clozapine and major metabolites in serum and urine. Ther Drug Monit 1997; 19: 480-488